secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2026-06-03T11:58:30+00:00
Accession:  0001193125-26-254615
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma shareholders approve 2026 ESPP, re-elect directors at AGM
-----------------------------------------------------------------------------

- Shareholders approved 2026 Employee Stock Purchase Plan; up to 1,150,000 ordinary shares available, 15% discount on lower of start/end market price.
- Purchase periods generally 6 months; payroll deductions 1%-15% of compensation; plan expires June 2, 2036.
- Re-appointed John W. Smither and Janneke van der Kamp as non-executive directors until 2030 AGM.
- Board authorized to issue shares (including without pre-emption rights) through June 2, 2031.
- Say-on-pay passed with 81.1M for; Deloitte ratified as auditor for FY2026; quorum 78.3%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/0001193125-26-254615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/nams-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-254615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer